

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32557A  
APPLICATION NO.  
10/520,359  
APPLICANT  
BREITENSTEIN ET AL.  
FILING DATE  
SEPTEMBER 12, 2005Group  
4614  
1624

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
DR	AA	5,516,775	5/14/96	Zimmermann et al.	-----	-----	
DR	AB	2006/0014742	1/19/06	Asaki et al.	-----	-----	
DR	AC	5,521,184	5/28/96	Zimmermann	-----	-----	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
DR	AM	02/46170	6/13/02	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AN	02/46171	6/13/02	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AO	0 588 762	3/23/94	EP (English equivalent is US 5,516,775)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AP	95/09853	4/13/95	WO	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
DR	AQ	2004/002963	1/8/04	WO (English equivalent is US 2006/0014742)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)


DR	AR	Zimmermann et al., "Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives," Bioorganic & Medical Chemistry Letters, Vol. 7, No. 2, pp. 187-192 (1997)
DR	AS	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) - Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors," Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 11, pp. 1221-1226 (1996)
DR	AT	Paul et al., "Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors," J. Med. Chem., Vol. 36, pp. 2716-2725 (1993)

EXAMINER /Deepak Rao/ DATE CONSIDERED 09/28/2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32557A  
APPLICATION NO.  
10/520,359  
APPLICANT  
BREITENSTEIN ET AL.  
FILING DATE  
SEPTEMBER 12, 2005Group  
4614  
1624

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
DR	BM	JP 6-184116	7/5/94	JP (English equivalent is US 5,516,775)	-----	-----	<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DR	BR	Bhat et al., "Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed Myeloid Cells," The Journal of Biological Chemistry, Vol. 272, No. 26, Issue of June 27, pp. 16170-16175 (1997)
DR	BS	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene ( <i>flt</i> ) closely related to the <i>fms</i> family," Oncogene, Vol. 5, pp. 519-524 (1990)
	BT	

EXAMINER

/Deepak Rao/

DATE CONSIDERED

09/28/2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.